The American pharmaceutical company Moderna announced on Thursday that it is developing a single-dose vaccine that combines a booster for Covid-19 with its experimental flu vaccine, Reuters reports.
The company hopes to eventually add vaccines to the respiratory syncytial virus (RSV) and other respiratory diseases, in the form of an annual vaccine.
“We believe we have a great opportunity ahead of us if we could bring a high-efficiency annual pan-respiratory booster to market,” Moderna CEO Stéphane Bancel said during a presentation to inform investors about the drugs. its developing.
“We believe that Moderna could be the first to use this important new opportunity,” he said.
The company is conducting clinical trials for an RSV vaccine in older adults.
Moderna and Pfizer / BioNTech are already expected to get billions of dollars from recalls for Covid-19, health analysts and investors said.
The addition of flu vaccines and other diseases could further increase these benefits.
Moderna shares rose 6.2% on Thursday, according to reports.
The pharmaceutical company is already developing several candidate influenza vaccines.
The new vaccine combines the company’s experimental influenza vaccine, which is the most advanced with its Covid-19 vaccine.
According to an analyst at Oppenheimer & Co., Hartaj Singh, the news that clinical testing of the combined vaccine could begin in the next 6-12 months was a positive surprise for investors.
Novavax, which does not yet have US authorization for its Covid-19 vaccine, said Wednesday it has launched an early-stage clinical trial to test the combined flu and Covid-19 vaccines.
The above article is for your personal information only. If you represent a media institution or company and would like an agreement to republish our articles, please email us at [email protected].
– .
